Revive Therapeutics Director Signs Manufacturing Arrangement With Vaxart
It appears that Revive Therapeutics (CSE: RVV) has a budding superstar on its board of directors. Last week, Revive’s independent
Read more
Revive Therapeutics
Revive Files IND Application With FDA For Phase 3 Clinical Study For COVID-19 Treatment
Revive Therapeutics (CSE: RVV) announced after the bell today that it has officially filed its investigational new drug (IND) application
Read more
Revive Therapeutics And The Psychedelic Revolution
A massive psychedelics boom is already here. In fact, with the potential to treat a wide range of mental and health
Read more
Revive Therapeutics Sees Research Partnership On Psilocybin Expanded
Revive Therapeutics (CSE: RVV) has expanded its sponsored research partnership agreement with that of the University of Wisconsin-Madison related to
Read more
Revive Files Clinical Trial Application With Health Canada, Releases Phase 3 FDA Study Design For Potential Treatment Of COVID-19
Revive Therapeutics (CSE: RVV) continues to advance its clinical trial efforts. The company announced this morning that it has filed
Read more
The Deep Dive Compiles Company Profile on Revive Therapeutics
The Deep Dive has assembled a company profile for that of Revive Therapeutics (CSE: RVV), a life sciences company focused
Read more
Revive Therapeutics To Investigate Novel Oral Dosage Forms Of Psilocybin
Revive Therapeutics (CSE: RVV) has provided an update to the market in regards to its psilocybin-based pharmaceutical program. Revive intends
Read more
Revive Therapeutics Advances Psilocybin-Based Product Research
Revive Therapeutics (CSE: RVV) this morning announced that it has partnered with Complete Phytochemical Solutions for the purpose of advancing
Read more
Revive Therapeutics Selects Novotech As APAC Contract Research Organization
Revive Therapeutics (CSE: RVV) this morning has continued its push towards studying Bucillamine as a treatment for infectious diseases. Revive
Read more
Revive Files Pre-IND Meeting With FDA For COVID-19 Treatment
Revive Therapeutics (CSE: RVV) this morning announced that it has filed its pre-investigational new drug (Pre-IND) meeting request with the
Read more